outperform
introduc coverag invest rate
outperform month price target repres nich player
up-and-com within burgeon consum healthcar space compani
proprietari ingredi niagen demonstr signific promis mean
allow peopl age better amongst attribut meaning near-term hurdl
persist said increasingli optimist manag
continu develop refin market messag sale niagen consum
world-wide pick significantli effect leverag larg capital-light
corpor infrastructur initi posit call long-term highli
specul natur
initi forecast impli steadi sale earn progress
look loss per share vs current street figur
predic upon total compani sale expans
ep forecast assum total compani sale impli
adjust ebitda ex legal expens
emerg global brand support scienc mani cellular function
relat health healthi age sensit level nad declin
human grow older niagen consum form niagen repres
clinic proven nad precursor rais nad level advers side
distribut infrastructur take shape oper
establish proprietari e-commerce infrastructur us elsewher
establish distribut relationship lead chain key geographi
across globe make distribut framework help support
outsiz sale growth compani time
pois aggress market product view
scienc behind niagen solid primarili pillar
distribut infrastructur place compani situat much
aggress market uniqu product could acceler meaning
sale earn expans
valuat underappreci l-t potenti initi month
price target predic upon dec enterpris valu gross
profit multipl level repres modest premium current
trade paramet consist multipl afford
year price histori
devot improv way peopl
analyst certif import disclosur see disclosur
total compani sale growth next sever year
niagen brand build behind stepped-up market
suppli chain cost synergi push gross margin closer
sale level current
reach profit
repres nich player up-and-
comer within burgeon consum healthcar space
compani proprietari ingredi niagen demonstr
signific promis mean allow peopl age better
amongst attribut meaning near-term hurdl persist
said increasingli optimist
manag continu develop refin market
messag sale niagen consum world-wide
pick significantli effect leverag larg capital-light
corpor infrastructur initi posit call
long-term highli specul natur
quarterli earn report
acceler regulatori approv allow signific expans
new market result top-lin upsid
favor legal develop result signific cost save
allow addit market spend behind niagen
reach profit earlier forecast
regulatori delay slow expans new market limit total
advers chang compani relationship nestl
requir addit capit beyond initi forecast
month price target predic upon dec enterpris valu gross profit multipl level
repres modest premium current trade paramet consist multipl afford similar type growth
risk price target includ broader slowdown consum spend stepped-up competit health well space
scientif studi contrari claim advers side effect current user potenti product recal on-going litig and/or patent
issu regulatori delay slow expans new market
note view stock trade specul appropri risk-toler investor
launch research coverag share
invest rate outperform month price target suggest
upsid potenti current level
devot improv way peopl age compani scientist partner
lead univers research organ across globe uncov
complet potenti nicotinamid adenin dinucleotid nad identifi
develop novel science-bas ingredi flagship ingredi
niagen nicotinamid ribosid sold directli consum niagen
support clinic scientif research well signific intellectu
capit upon develop relationship expand number
lead distribut partner includ fullscript watson health
initi posit assess compani share
predic upon follow key factor
potenti widespread expand global consum demand
anti-ag product servic serv healthi backdrop
facilit outsiz top- bottom-lin growth
outlook still nascent rapidli develop increasingli
power multi-facet distribut network anchor company-
oper websit strateg retail partnership world-wide allow
satiat effect strengthen consum demand
compani key ingredi niagen niagen particularli
compani strengthen market effort
increasingli clear signal oper
compon financi statement
prospect intellectu properti protect nicotinamid ribosid
nr cdxc statu exclus license patent
allow compani continu effect studi market
molecul absent threat meaning competit incurs
share valuat believ significantli underappreci near-
long-term sale earn power
extend expand coverag
past sever month work expand enhanc
consum growth e-commerce coverag univers includ larger number
high-qual oper across broader space particular disruptive-
type enterpris capit effect power digit technolog
connect better consum enhanc underli busi process
client look upon initi latest effort
enhanc expand coverag initi foray burgeon
sever notabl recent initi includ
wayfair introduc coverag wayfair
lead player realm busi consum on-line commerc
focus upon expans home furnish sector
ww ww introduc coverag ww formerli weight watcher
work name highlight effort
senior manag reconfigur compani busi model
connect consum digit mean
updat websit enhanc app
lead athleisur luxuri brand later re-launch
coverag number compani athleisur luxuri sector
nike lululemon
studi written extens way oper
util effect improv technolog capabl
lovesac sever week ago initi coverag lovesac
nich player within home furnish space
design manufactur uniqu patent protect seat product
refer sac saction connect consum
combin compani own digit enhanc store
partnership lead tradit retail costco
proprietari websit
carvana recent introduc lengthi launch report
on-line use car seller highlight extens
compani leverag technolog backbon asset-light busi
model disrupt still fragment ineffici business-to-
consum market late-model pre-own vehicl us
initi call long-term specul
want state clearli discuss throughout initi report
introductori posit call share long-term focus
highli specul
mani way trajectori share apt prove binari
natur albeit potenti upsid long-term easili exceed downsid
risk near term henc invest rate outperform
intrigu potenti lead patent protect product
niagen view compani busi model begin leverag
support significantli stronger sale profit road
said meaning oper financi risk remain includ
pertain govern regul potenti need futur
capit rais could impact trajectori share nearer term
even prove fundament hurdl compani come quarter
continu studi close updat invest think
compani share need
cheat sheet scienc behind
given histori expertis
close cover consumer-ori
enterpris invest research work focu primarili
consum aspect compani develop busi modelit
structur financi disciplinesa make-up competit landscap
oper
said core repres science-bas organ
analyst follow recommend work copious
expand mindset understand well impress scienc behind
compani lead ingredi niagen niagen
throughout report highlight stringent scientif process help
underpin uniqu strategi busi model
meantim follow ten key point serv cheat sheet client
seek quick summat scienc underpin core
mani cellular function relat health healthi age sensit
level local avail nicotinamid adenin dinucleotid nad
nad level constant human shown
declin young adulthood middl age
research demonstr decreas nad render bodi greater
risk neuro muscular degener declin cardiometabol
health diminish capac cellular repair resili
nr novel form vitamin compani introduc
ingredi commerci form trade name niagen
data numer anim studi confirm human clinic
trial show nr highli effici nad precursor significantli
rais nad level advers side effect
nr compound found natur milk trace amount
exist variou compound belong vitamin
famili molecul structur uniqu therefor process
differ way bodi research suggest nr
effici ingredi boost nad level
recent publish clinic studi univers colorado
show niagen lift nad level also elev level
adenosin triphosph atp better known energi within bodi
niagen twice success review
program success notifi fda gener
recogn safe gra
current
collabor wherebi compani scientist partner
lead univers research organ across globe
uncov full potenti nad identifi develop novel
science-bas ingredi
possess strong portfolio intellectu properti around
niagen own licens global patent patent
pend compani lead patent exclus licens
har power digit
note extens research work broader consum
sector emerg digit technolog across space serv
empow consum afford well-posit nimbl oper
abil better manag grow enterpris
uniqu coverag compani repres science-
base manufactur distributor patent protect health supplement
said client look upon launch coverag first
foremost anoth step effort diversifi consum
coverag highlight uniqu oper har power digit
technolog enhanc underli oper connect consum
endeavor build flagship product niagen
niagen global consum brand respect consum
forefront anti-ag scienc appeal nich shopper well
note recent work name lovesac
carvana even nike lululemon among other
prolifer digit technolog emerg e-commerce
allow come brand quickli connect directli target
consum also serv strengthen underli busi model
brand size increasingli util power digitally-driven
mass market advertis effort particularli newer platform
social media email lieu tradit market tool often prove
less effect costli
outlin later piec merit still develop yet increasingli
power distribut network support grow
proprietari e-commerce presenc us elsewher strateg
partnership lead retail key intern market
past sever year manag compani
team scientif advisor work invest aggress test
refin flagship ingredi niagen niagen
view core product prime assert
introduct adopt consum across globe
studi close come away opinion
key opportun compani stakehold invest
dynam enhanc market engin spread word
amongst health conscienc athlet perform mind consum
world-wide niagen niagen help improv way live
compet
alreadi employ power digit connect consum
expect emerg practic direct e-commerce fulfil
target on-line centric market enhanc effort time
consid long ago compani product
niagen niagen beholden larg retail
suscept prohibit costli mass market advertis develop
brand like other capit effect upon quickli chang
paradigm us elsewher
initi studi prospect compani come away
upbeat upon key factor long-term potenti compani
uniqu niagen niagen ingredi expans size compel
growth potenti health supplement sector us across globe
underli leverage- prowess compani develop
distribut infrastructur overal busi model
niagen uniqu potenti power health supplement
niagen repres world first commerci avail natur
ident form nicotinamid ribosid nr
nr next-gener form vitamin act potent
bioavail booster nicotinamid adenin dinucleotid nad nad vital
function ensur proper cellular energi metabol enabl
mitochondria powerhous cell convert food peopl eat
energi bodi need sustain function
mani year scientif research demonstr supplement nr
effect boost nad level anim human
accord research paper publish us-bas nation
institut age evid suggest nad declin occur variou
tissu age process bolster cellular nad level might
suppress aspect age forestal age-rel diseas
exhibit nr proven boost nad level declin natur overtim
possess exclus licens produc nr supplement
compani restructur busi model focu upon product
singularli introduc niagen year later
launch niagen consum target form niagen
niagen price per bottl depend mani bottl
purchas whether part recur auto-ship subscript
univers iowa biochemistri professor dr charl brenner serv chief
scienc advis tenur faculti member
dartmouth colleg dr brenner initi discov nr vital precursor
nad past decad dr brenner paramount advanc
research nr nad
hong kong-bas billionair busi tycoon li ka-sh repres key
forc behind recent transform build
april rais capit assist compani
transit consum product compani organ focus upon
horizon ventur invest today li variou
entiti own approxim
addit li invest sinc rais
privat placement common stock issuanc convert note
exhibit effect rais signific capit number offer past year
watson health beauti chain own ck hutchinson hold
compani control li famili introduc niagen septemb
discuss later report cdxc distribut allianc
watson hong kong repres key compon compani
ninety-one-year old li ka-sh broad-bas advoc anti-ag effort
take niagen sinc introduc compani
health supplement sector expans grow
per key sourc market health well nutrit
supplement us across globe expans grow
believ help creat solid sustain demand backdrop
particularli compani turn even vigor market brand
global busi youth greater report publish
june orbi research indic world-wide
spent busi youth includ skin care
cosmet surgeri hair restor fit vitamin supplement
orbi expect world-wide anti-ag market expand
compound annual growth rate gagr nearli
vitamin dietari supplement market euromonitor
estim global market vitamin
dietari supplement measur figur research
group expect expand compound-annual-growth-rate
investor present manag point three
everi four american take dietari supplement number
well supplement market global rel domin hand
major player given natur sector still lend well upstart
apr stock splitdirect offeringcredit facilitypriv placementpriv placementissu convert notespriv placementcommon stock ratio per sharebridg credit facilityshar may sold uscommon per sharenot convert per sharecommon per sharesatisfi nasdaq list requirementspay exist debt facil capit needsthre part strateg invest led li ka-shingintern domest init clinic research gener corp purposesintern domest init clinic research gener corp purposesintern domest init clinic research gener corp note figur reflect gross amount fee expens outperform
view notic exhibit sale seven top nutrit well
compani account nearli annual nestl nutrit
scienc one largest player sale annual notabl
decemb initi strateg relationship nestl
wherebi suppli nestl niagen ingredi form includ
compani nutrit product boost current
nestl pre-market test commerci anticip
exhibit vitamin dietari supplement market rel domin hand major player
remain earli stage develop compani
proprietari product still larg unknown mass market consum
past coupl year primarili stewardship new ceo
former outsid director rob fri transform
ingredi standard qualiti assur compani consumer-focus
marketing-driven organ help world age better
compani histori ingredi compani led discov formul
signatur product niagen consum form niagen
key differenti within expans health supplement space
desir compani effect distribut product
custom also scienc behind product importantli
remain leader research nr nad
end partner extens high calib research
organ continu understand better full potenti proprietari
aug exist on-going complet publish clinic trial
regist clinicaltri gov
pharmacokinet
therapeut effect nr anoth five clinic trial regist test nr
combin ingredi bring total number studi
salesnestl nutrit ltd total daniel midland plc perform nutrit nutrit hold inc total skin enterpris
exhibit own scienc behind niagen product
year
age categori
june niagen recogn nutralngredients-usa winner
ingredi
acknowledg commit qualiti clinic research
regulatori complianc organ herald niagen breakthrough
ingredi point deliv promis address true
mechan cellular age wherea product might focu
symptom age
view primari compel aspect invest stori
potenti compani expand capit upon alreadi
consum direct channel retail partnership us canada
hong kong singapor new zealand sell cross-bord uk
japan china
exhibit chromadex distribut still earli stage expand rapidli
began sell niagen ingredi on-line direct consum
us niagen brand earli sinc launch
niagen compani expand distribut domest includ
sell via third-parti platform major on-line player notabl amazon
well healthcar practition partnership natur
expand canada via cross-bord channel
receiv regulatori approv region oct manag indic
sale momentum continu build steadili market heel
distribut partnership fullscript canada health showcas
recent whole food compani seven locat ontario
addit partnership key retail canada also connect
consum proprietari websit truniagen ca amazon
second quarter period end june announc two soft
japan
manag expect matur time given strong cultur health
well dietari supplement region
china anoth
flagship distribut infrastructur compani
partnership watson hong kong niagen sold
june manag indic compani continu
experi strong sell hong kong particularli follow recent
celebr video post went viral discuss later expect hong kong
remain key market concern somewhat social unrest
region could weigh upon new consum adopt niagen
compani distribut partnership watson singapor remain
work progress seem demonstr improv top line momentum
new market public relat effort take hold
exhibit partnership watson hong kong repres compon cdxc distribut network
compani file opco estim
next big area focu europ aug compani
receiv posit opinion nr european food safeti author
efsa critic step eu regulatori approv process manag
tent expect launch niagen europ watson
major partner region across germani uk alon watson
exhibit opportun expand chromadex partnership watson global remain plenti
refin enhanc market effort
thu far hesit outlin detail key metric regard
underli perform custom cohort effici
convers senior
sale watson store sell niagenavg sales/storewatson hong total total watson total watson sale provid quarterli earn presentationswatson storesgermanypolandunit kingdomnetherlandseurop
leadership impli posit better disclosur
importantli manag point june releas higher sale
return custom repres primari driver sale growth
period suggest better market effici compani view
continu regularli test market effort particularli
pertain compani e-commerce effort us elsewher
effort maxim advertis spend drive lower cost custom
overal market yet reach tip point
consum awar brand dynam nad broadli
continu refin market messag test
implement new ad campaign ground solid foundat
scienc behind key ingredi niagen
recent compani launch new market campaign entitl
believ highlight number influenc celebr tout merit
niagen
person util campaign includ
strauss zelnick ceo take-two zelnick media
dr alyssa dweck practic gynecologist name top doctor new
york magazin westchest counti
gabriel reec former pro beach volleybal player health
adam vinatieri placekick indianapoli colt
shannon sharp fame former footbal player
increasingli focus market effort upon target fitness-
orient consum firstli ad campaign featur shannon sharp
expand line-up radio televis spot manag
indic continu develop relationship profession athlet
sport team compani remain earli stage develop
aspect busi alreadi contact number trainer
coach interest research nicotinamid ribosid
state onset piec view potenti turn
aggress market effort repres key strateg opportun
compani potenti meaning driver even better sale growth
much need sustain catalyst share
n-t risk persist
indic earlier report upon initi inspect
come away quit encourag intrigu long-term prospect
compani share nonetheless view invest highli
specul natur compani key product yet garner mass
market accept given number still preval nearer-term challeng
compani
view potenti nearer-term challeng includ
on-going
on-going litig remain unknown current
litig compet supplement
manufactur market elysium regard breach contract
patent infring recent develop situat
occur oct california judg overse case delay
trial schedul oct request addit inform
pertain firm damag elysium
theft trade secret
legal expert difficult time underwrit
invest thesi pertain lawsuit said studi
close on-going disput elysium
view clearli right complex matter
time optimist court california elsewher
rule favor process help creat much fairer
ethic play field compani proprietari
ingredi nearer-term howev remain concern
on-going litig elysium apt remain costli
impact overal consum messag regard health benefit
nicotinamid ribosid new ingredi countri around
globe expand global footprint new geographi
compani need obtain regulatori approv ingredi
product niagen niagen certain
instanc must obtain approv market
pace govern approv notori slow cumbersom
larg hand senior leadership
compani therefor remain concern on-going delay
govern approv could repres continu headwind sale
growth
hong kong unrest persist per number measur recent social
unrest hong kong weigh meaning upon abil
desir consum region shop monitor
develop hong kong assess potenti disrupt legaci
compani coverag given initi
success niagen hong kong store watson
discuss greater detail later piec concern somewhat
recent develop could somewhat impact sale expans
compani overal expect social unrest hong kong
like impact demand new custom rather
shopper alreadi buy take niagen
model care near- long-term financi project
take consider histor trend compani
expect busi go forward healthi degre
conservat given nearer-term challeng continu present
per estim expect could return capit market
addit financ like bolster oper cash cushion
requir past coupl year effect rais capit
number note investor afford us confid abil
compani return market larg without issu
new
share weaker late reflect n-t challeng
notic exhibit share current track
recent high set may thu far
versu gain newli creat
consum univers view recent weak share
reflect primarili threat nearer-term factor upon compani
on-going legal issu recent unrest hong kong aggrav lack
exhibit n-t concern lack investor sponsorship weigh upon late
recent result demonstr improv leverag
report june result aug indic loss per share
vs prior-year period street figur
overal result second quarter reflect healthi combin
continu strong top line expans strengthen gross margin improv
opco consum growth e-commerce coverageopco consum health univers indexsinc august recent close price prior jun earn announc base intra-day price result use indic futur includ biog b-se cvsi iph nept-ca taro outperform
june total compani revenu improv year-on-year
sequenti sale niagen account
total compani revenu june expand year-on-year
sequenti gross margin period rose bp
june adjust ebitda exclud legal expens
june track loss better loss prior year
sequenti adjust ebitda exclud legal expens improv
loss first quarter period end march
end june cash compani balanc sheet total
includ convert note issu may subsequ
end second period rais addit anoth extern
financ bring compani pro forma end june cash balanc
detail key compon recent june announc
exhibit
exhibit result illustr improv leverag within busi model
compani file factset
manag provid standard financi guidanc
outlin qualit comment regard near-term expect
busi
strong top line growth primarili driven sale niagen
compani us e-commerce busi intern
partnership watson well distributor cross-
border opportun certain new oversea market partial off-set
continu declin legaci ingredi busi
gross margin continu expand sale niagen
grow result cost save throughout suppli chain
sell market expens percentag sale track
new custom
acquisit compani diversifi market effort
beyond digit direct respons effort absolut term
sell market cost apt climb
implement new effort track custom behavior
gener administr expens expect track
million dollar absolut term notch lower percentag
sale
resultsconsensusannu guidanceconsensuscdxc total sale growth bpssale dollar bp adj ebitda bpsearn per
june indic compani longer
achiev cash flow break-even fourth quarter earli
due on-going elev legal cost like elev fluctuat
new custom
pertain
term long-term expect manag indic assum
quarterli oper expens exclud extra legal cost
gross margin june impli potenti
 break-even quarterli sale total compani sale
june
exhibit manag indic improv sale leverag expens deliv total compani profit
manag point higher gross margin occur result
sale mix shift toward niagen key suppli chain initi
begin occur take hold
initi strateg relationship nestl dec wherebi
suppli nestl niagen ingredi form includ
compani nutrit product boost part strateg
agreement nestl paid initi fee leadership
indic agreement nestl could prove quit benefici longer
term expect meaning revenu growth deal
exhibit limit launch niagen nestl nutrit product expect
break-even frameworkchromadex revenu oper oper expens ebitda margin excl equiti compens depreci amort incl legal expens must met unless deadlin extend nestlemileston paymentspost launchkey right niagen medic nutritionco-exclus right niagenin certain protein base beveragesnorth america europ latin america australia japan new zealandpartnership chromadexaddit commercialmileston payment tochromadexchromadex reciev tier royaltiestechn feasibl requir stabil ready-to-drinkformatlimit launch commercializationlarg scale launch loos powder ready-to-drink productpay termsupfront payment outperform
key compon initi dilig studi
close histor financi compani review myriad sector
market data subsequ construct detail model
forecast adjust loss per share vs current street
figur upon total compani sale
prior year compar consensu forecast
adjust ep forecast compar current street figur
predic upon total compani sale vs current
consensu estim suggest year-on-year expans
look toward expect earn per share vs current
street figur predic upon total compani sale
prior year current consensu forecast
outer year ep forecast compar current street figur
predic upon total compani sale roughli
adjust ebitda ex legal expens
current cover sell side analyst given still small
base coverag lack financi guidanc manag near-
long-term hesit look upon street financi forecast
compani good indic underli market expect
detail compon upbeat long-term annual financi outlook
appendix page
set announc sept result earli novemb
sept forecast loss per share compar current
street figur predic upon total compani sale
vs current consensu forecast gross margin expans
bp prior-year period
predic posit near- long-term financi outlook chromadex
upon follow key point
sustain outsiz sale growth niagen brand build
grow
approxim annual driven increas niagen
sale somewhat off-set modest declin legaci line busi
ingredi analyt refer standard servic
exhibit strengthen sale niagen fuel outsiz top-line expans forese futur
compani file opco estim
exhibit e-commerce driven sale expect repres compon improv top line trend
expect e-commerce continu fuel major niagen
sale growth proprietari third parti platform follow
expand relationship watson
compani file opco estim
initi jump sale follow launch niagen
e-commerce trend similarli subscript busi
recent exist custom requir constant replenish
quarter similar recent trend equat
approxim growth year-over-year annual
estim e-commerce sale growth year-over-year moder
potenti aggress market upsid
exhibit e-commerce sale trend similarli subscript busi
next major unlock sale like follow regulatori approv
europ aug receiv posit opinion nr
consum product sale ingredi analyt refer standard figur reflect current opco niagen consum product salesexpectedto grow total compani sale greater expansioninto europ add niagen sale outperform
european food safeti author efsa critic step
eu regulatori approv process previous note manag
tent expect launch niagen europ
base convers manag expans watson
across europ like follow shortli thereaft regulatori approv
watson door across germani uk initi target
assum expand niagen watson door
moder overtim brand gain greater awar
conserv estim watson europ could add approxim
sale assum approv mid-year expand
sale comparison estim
watson sale across hong kong singapor store total
exhibit watson repres distribut partner europ time
compani file opco estim
potenti n-t top line weak social unrest hong kong
persist per number measur recent social unrest hong kong
weigh meaning upon abil desir consum
region shop exhibit highlight recent commentari
lvmh hugo boss manag team regard impact
hong kong protest busi
exhibit recent commentari lead brand impli backdrop hong kong might worsen
watson store sell niagen quarterli sales/stor market quarterli sales/stor watson europ estimate quarterli estimateslvmh moet hennessi loui vuitton earn call drop busi roughli drop hong kong combin flattish month juli around drop august septemb definit trend worsen throughout quarter situat littl bit better wholesal busi littl bit wors retail busi name fashion leather jewelri dont number last week yet given fact closur store situat get better would surpris turn better number fashion week global situat havent seen mani mani countri boom consequ situat difficult draw correl variou geographi particularli asia busi macau notch higher use compens realli dont know difficult figur whether realli offset factor asian geographi due situat hong kong mani mani chang non-hong kong geographi term growth everyth go fine go better due difficulti hong kong hugo boss boss-d preliminari busi hong kong substanti neg affect sinc begin polit unrest demonstr chromadex
math sale store hong kong account roughli
total watson busi approx total chromadex
sale concern somewhat recent develop could
impact continu sale growth region particularli regard
exhibit sale hong kong account estim total compani revenu
compani file opco estim
steadili improv gross margin sale niagen account
larger portion overal revenu part
quarterli break-even framework manag expect gross margin
reach approxim nearer term anticip shift higher
margin niagen sale legaci ingredi busi
major driver continu gross margin expans suppli chain
initi ad tailwind begin
exhibit continu shift sale higher margin niagen on-going gross margin tailwind
substanti uptick expens fuel growth manag
expect spend moder somewhat near term total oper
expens equat approxim quarter forecast
oper expens roughli flat around target per
quarter estim total oper expens dollar
begin increas market expand
watson watson hong kong hong kong watson hong kong sale sale calcul base averag estim sale per store hong kong total watson sale kong total chromadex sale marginconsum ref std gross outperform
exhibit expens growth anticip moder come year follow outsiz invest
compani file opco estim
potenti abat legal cost allow greater market
invest estim model continu
heighten gener administr expens given uncertainti
relat closur outstand legal matter elysium
expect compani transit save lower legal fee
aggress market
momentum legal expens equat approxim
exhibit wind legal expens could allow nearli spend per quarter shift market
indic earlier report identifi increasingli clear
indic financi leverag believ compani
path toward sustain profit necessarili look upon
achiev capit self-suffici
end june cash balanc sheet bolster
capit rais period payment nestl first
quarter year period end march subsequ end june
rais anoth make pro forma june end cash
balanc roughli
oppenheim co help facilit recent capit rais effort
detail cash analysi exhibit notic
expect annual cash burn compani track
 marketingresearch developmentgener legal
consid yearli cap expenditur roughli work capit
need approxim analysi impli cash
balanc sheet apt bottom fourth quarter
begin rebuild compani turn sustain profit
view financi forecast impli cash neg
scenario compani next year expect
manag could return capit market potenti fund
step market campaign and/or build cushion balanc
compani file opco estim
initi month price target predic upon
enterprise-value-to-gross profit multipl timesa level
modest premium current trade paramet larg
consist valuat afford share similar slower expand
exhibit price target predic upon ev/gross profit multipl
compani file opco estim
net incom base account work use oper gross curent share opco target equiti share share price gross profit analysisenterpris outperform
detail compar compani valuat analysi appendix
page
assign price target early-stag consum growth stori
easi consid valuat share trade
construct upon indic improv sale growth margin
expans compani healthi multipl afford similar type
enterpris often expand much less robust rate
nearer term rule potenti continu volatil
even weak share notic exhibit share
recent retreat toward level consist prior trough illustr
exhibit past sever quarter indic
outsiz sale growth serv solid support multipl
share trade
factset opco estim
exhibit on-going outsiz sale expans help support share valuat n-t
factset opco estim
factor invest rate price target
potenti compani purchas either larger corpor
financi entiti said consid prospect
potenti consum demand compani proprietari ingredi
expand substanti believ compani could turn quit compel
current level short interest total float track
upward strateg plan continu take shape
path toward sustain profit compani turn clearer expect
short-cov apt occur could repres rel meaning driver
share price appreci
appendix detail behind initi estim
factset opco estim
million opco newconsensusguidanceopco newconsensusopco newconsensusopco newconsensustot bpstotal oper mktg oper expens mktg significantli pt significantli pt oper ptsnet dec dec dec dec
factset opco estim
scienc inc hold corp well solut consum healthcar pharmaceut industri ltd inc scienc inc hold corp well solut nept-ca cad consum healthcar pharmaceut industri ltd inc base opco estim sale gross profit actual exclud discontinu lab busi sold enterpris valu salesenterpris valu gross profitsal growth rategross profit growth rate outperform
compani report opco estim
chromadex quarterli incom statement analysisfisc year end dec dollar thousand except per share datafirst quartersecond quarterthird quarterfourth oper incom per averag oper ebitda sale sale oper
appendix statement flow
compani report opco estim
chromadex annual statement flow analysisfisc year end dec dollar thousand except per share flow oper activitiesnet incom compens dispos properti oper asset liabilitiesacccount expens payabl accru use oper flow invest activitiesproce dispos leasehold improv intang sale invest long-term use invest flow financ activitiesproce issuanc common stock net issuanc exercis stock common sale convert convert note issuanc loan debt issuanc payment loan paid debt extinguish payment capit leas use provid financ increas decreas equival begin equival end outperform
compani report opco estim
chromadex balanc sheet analysisfisc year end dec dollar thousand except per share account expens total current leasehold impov equip non-current held escrow net allow invest relat party- non-current asset held sale- long-term current liabilitiesaccount matur loan payable- current matur capit leas deposit rent officer- total current loan payabl less current maturities- capit leas oblig less current rent less stockhold equitycommon paid-in total stockhold liabil stockhold
appendix manag board member profil
execut manag teamnamebackground/responsibilitiesfrank jaksch jr co-found execut chairman boardrobert friedchief execut officerkevin farrchief officerlisa bratkovichchief market officermatthew robertschief scientif offic senior vice presid innovationgeorg hillexecut vice presid retail operationsben schichmanchief technic officermegan jordanchief offic senior vice preseid global public affairsboard directorsnameboard tenurepositionfrank jaksch yr chairman board co-found rob yr director chief execut offic stephen yr non-execut director chair compens committe member audit committe jefferi yr non-execut director presid ceo director inc kurt yr non-execut director chief financi offic princip account offic execut vice presid incsteven yr non-execut director member nomin corpor govern committe wendi yr non-execut director member nomin corpor govern committe frank jaksch jr co-found compani serv member board sinc februari mr jaksch serv chairman board may octob co-chairman februari may june mr jaksch transit chief execut offic execut chairman board mr jaksch overse research strategi oper compani focu scientif novel product pharmaceut nutraceut market mr jaksch serv intern subsidiari manag phenomenex life scienc suppli compani manag intern subsidiari intern busi develop divis robert fri becam chief execut offic june serv director compani sinc juli presid chief oper offic januari june presid chief strategi offic march januari mr fri also serv member nomin corpor govern committe juli march mr fri serv chairman board director tiger media inc amex idi inform solut provid focus data fusion market june presid chief execut offic director ideat acquisit corpor special purpos acquisit compani kevin farr serv chief offic sinc octob mr farr previous serv chief offic inc februari septemb prior serv multipl leadership role sinc join mr farr spent year pricewaterhous cooper mr farr serv corpor advisori board marshal school busi univers southern california board member polari industri inc lisa bratkovich serv compani chief market offic sinc june ms bratkovich join direct upsid group direct-to-consum market custom experi transform consult firm serv ceo princip sinc prior start firm ms bratkovich spent year guthy|renk serv senior vice presid market ms bratkovich spent career grow refin brand market custom experi numer direct-to-consum product notabl help catapult brand proactiv meaning beauti renown health beauti brand hundr million dollar annual revenu dr matthew robert receiv ph environment compar toxicolog cornel univers olin school busi washington univers plant molecular biolog physiolog purdu univers accomplish innov execut year success abbott nestl natur bounti compani pharmavit dr robert focus drive growth-phas market opportun across food nutrit agricultur sector learn mean addit manag enjoy ride sale forc work shift factori field particip laboratori whenev possibl megan jordan serv compani chief offic senior vice presid global public affair sinc august previous ms jordan senior vice presid global corpor commun herbalif nutrit respons defin manag execut compani commun strategi world-wide role jordan overse compani intern extern commun social media content strategi thought leadership advertis herbalif nutrit product sold countri network independ distributor mr hill join execut vice presid oper may prior join mr hill serv senior vice presid retail oper dick sport good sport good retail previous mr hill senior vice presid offic suppli retail shichman serv compani chief technolog offic sinc april mr shichman recent serv execut vice presid investcloud manag global data center oper prior vice presid technolog guidanc lead e-commerc system consult guidanc mr shichman serv iconstitu manag day-to-day busi oper direct product engin activ mr shichman serv number senior manag role outperform
stock price compani mention report
